Achaogen Announces All Objectives Met in Phase 2 Plazomicin Complicated Urinary Tract Infections Study and Start of First-in-Human Study with ACHN-975 – Business Wire

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Achaogen, Inc. announced today that all objectives were met in the company’s multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI …

Leave a Reply

Your email address will not be published.